Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
survival rates
Biotech
Gilead, Arcus keep TIGIT dream alive with 27-month OS data
Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of almost 27 months.
James Waldron
Oct 13, 2025 7:05am
FDA draft recommends all cancer trials collect OS data
Aug 20, 2025 10:59am
AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail
Sep 10, 2024 6:00am
Differences in survival spark FDA hold on Oncopeptides' drug
Jul 8, 2021 8:05am
Takeda takes on multiple myeloma outcomes study, as Ninlaro flounders
Aug 31, 2016 8:00am
